Parkinson's disease dementia

Last updated

Parkinson's disease dementia (PDD) is dementia that is associated with Parkinson's disease (PD). [1] Together with dementia with Lewy bodies (DLB), it is one of the Lewy body dementias characterized by abnormal deposits of Lewy bodies in the brain. [2] [3] [4] [5]

Contents

Parkinson's disease starts as a movement disorder, but progresses in most cases to include dementia and changes in mood and behavior. [6] The signs, symptoms and cognitive profile of PDD are similar to those of DLB; [2] DLB and PDD are clinically similar after dementia occurs in Parkinson's disease. [5] Parkinson's disease is a risk factor for PDD; it speeds up decline in cognition leading to PDD. [2] Up to 78% of people with PD have dementia. [2] Delusions in PDD are less common than in DLB, [2] and persons with PD are typically less caught up in their visual hallucinations than those with DLB. [7] There is a higher incidence of tremor at rest in PD than in DLB, and signs of parkinsonism in PDD are less symmetrical than in DLB. [8]

Diagnosis

Parkinson's disease dementia can only be definitively diagnosed after death with an autopsy of the brain. [6] The 2017 Fourth Consensus Report established diagnostic criteria for PDD and DLB. [9] The diagnostic criteria are the same for both conditions, except that PDD is distinguished from DLB by the time frame in which dementia symptoms appear relative to parkinsonian symptoms. DLB is diagnosed when cognitive symptoms begin before or at the same time as parkinsonism. Parkinson's disease dementia is the diagnosis when Parkinson's disease is well established before the dementia occurs; that is, the onset of dementia is more than a year after the onset of parkinsonian symptoms. [9]

Treatment

Cognitive behavioral therapy can help people with Parkinson's disease with parkinsonian pain, insomnia, depression, anxiety, and impulse disorders, if those interventions are properly adapted to the motor, cognitive and executive dysfunctions seen in Parkinson's disease, including Parkinson's dementia. [10]

Pathophysiology

Parkinson's disease dementia may have a mechanistic basis in neuroinflammation and alpha-synuclein aggregation [11] [12] involving the spreading of misfolded alpha-synuclein aggregates. [11] After initiation of neuroinflammation, IL-1β cytokines and CD4+ T-cells are hypothesized to activate to amplify the pro-inflammatory response of neurons that promotes neuronal dysfunction resulting in dementia. [11]

One hypothesis is that harmful environmental factors, such as toxins, infections, and poor lifestyle-factors, have been linked to triggering oxidative stress, inflammation, and selective vulnerability of dopaminergic neurons, which can lead to senescence, a state of permanent non-proliferation, or complete cell death. [11] Through senescence of neurons, alpha-synuclein pathology spreads, which amplifies inflammation, which leads to cognitive decline in PDD patients. [11] [13] It has been proposed that when Lewy body disease is in an advanced stage where alpha-synuclein pathology spreads and neuronal degeneration appears, PDD may develop. [13] In this hypothesis, a primary pathway toward progression of PDD is described to begin at the olfactory and limbic regions, which will cause parkinsonian motor symptoms and slowly progress to PDD. [13] Alpha-synuclein aggregation can begin in the olfactory bulb and travel to the limbic system. [11] [12] [13] A "brain-first" model and "body-first" model of the progression of PDD have been proposed to describe routes of alpha-synuclein pathology. [11] [12] [13] The "body-first" model of PDD connects enzymatic GBA mutations and ingestion of external toxicants, like contaminated food or water, to the spreading of alpha-synuclein pathology via the vagus nerve and sympathetic pathways to the brainstem and peripheral organs from the enteric nervous system. [12] [13] The "brain-first" model that induces slower progression of PDD connects LRRK2 mutations and inhaled external toxicants, like airborne pesticides and pollutants, to the spread of neuronal senescence and alpha-synuclein pathology from limbic regions to the brainstem and the substantia nigra. [11] [12] [13]

External environmental factors have been linked to inducing glial dysfunction and senescence. [11] When glial cells encounter a harmful environmental factor, they express a pro-inflammatory response and oxidative stress. [11] Air pollution as a harmful environmental factor has been linked to increased alpha-synuclein pathology, which promotes neuroinflammation. [12] Infections, such as periodontitis, as a harmful environmental factor can trigger an immune response and promote neuroinflammation. [14] Bacterial infections lead to IL-1β cytokine release, which can produce oxidative stress that promotes neuroinflammation. [14] The promotion and occurrence of neuroinflammation has been important in predicting possible neurodegenerativity. [14]

Society and culture

General awareness about LBD lags well behind that of Parkinson's and Alzheimer's diseases, even though LBD is the second most common dementia, after Alzheimer's. [15]

References

  1. Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM (2017). "Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies". F1000Res (Review). 6: 1604. doi: 10.12688/f1000research.11725.1 . PMC   5580419 . PMID   28928962.
  2. 1 2 3 4 5 Gomperts SN (April 2016). "Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia". Continuum (Minneap Minn) (Review). 22 (2): 435–63. doi:10.1212/CON.0000000000000309. PMC   5390937 . PMID   27042903.
  3. Pezzoli S, Cagnin A, Bandmann O, Venneri A (July 2017). "Structural and Functional Neuroimaging of Visual Hallucinations in Lewy Body Disease: A Systematic Literature Review". Brain Sciences (Review). 7 (12): 84. doi: 10.3390/brainsci7070084 . PMC   5532597 . PMID   28714891.
  4. Galasko D (May 2017). "Lewy Body Disorders". Neurologic Clinics (Review). 35 (2): 325–338. doi:10.1016/j.ncl.2017.01.004. PMC   5912679 . PMID   28410662.
  5. 1 2 Walker Z, Possin KL, Boeve BF, Aarsland D (October 2015). "Lewy body dementias". Lancet (Review). 386 (10004): 1683–97. doi:10.1016/S0140-6736(15)00462-6. PMC   5792067 . PMID   26595642.
  6. 1 2 "Lewy body dementia: Hope through research". National Institute of Neurological Disorders and Stroke. US National Institutes of Health. December 8, 2017. Retrieved April 6, 2018.
  7. Burghaus L, Eggers C, Timmermann L, Fink GR, Diederich NJ (February 2012). "Hallucinations in neurodegenerative diseases". CNS Neuroscience & Therapeutics (Review). 18 (2): 149–59. doi:10.1111/j.1755-5949.2011.00247.x. PMC   6493408 . PMID   21592320.
  8. St Louis EK, Boeve AR, Boeve BF (May 2017). "REM sleep behavior disorder in Parkinson's disease and other synucleinopathies". Movement Disorders (Review). 32 (5): 645–58. doi:10.1002/mds.27018. PMID   28513079. S2CID   46881921.
  9. 1 2 McKeith IG, Boeve BF, Dickson DW, et al. (July 2017). "Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium". Neurology (Review). 89 (1): 88–100. doi:10.1212/WNL.0000000000004058. PMC   5496518 . PMID   28592453.
  10. Zečević I (March 2020). "Clinical Practice Guidelines Based on Evidence for Cognitive-Behavioral Therapy in Parkinson's Disease Comorbidities: A Literature Review". Clinical Psychology & Psychotherapy (Review). 27 (4): 504–514. doi:10.1002/cpp.2448. PMID   32196842. S2CID   214601157.
  11. 1 2 3 4 5 6 7 8 9 10 Lau VZ, Awogbindin IO, Frenkel D, Whitehead SN, Tremblay MÈ (June 2025). "A hypothesis explaining Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies overlap". Alzheimer's & Dementia. 21 (6) e70363. doi:10.1002/alz.70363. PMC   12173844 . PMID   40528299.
  12. 1 2 3 4 5 6 Dorsey ER, De Miranda BR, Horsager J, Borghammer P (2024). "The Body, the Brain, the Environment, and Parkinson's Disease". Journal of Parkinson's Disease. 14 (3): 363–381. doi:10.3233/JPD-240019. ISSN   1877-7171. PMC   11091648 . PMID   38607765.
  13. 1 2 3 4 5 6 7 Borghammer P, Okkels N, Weintraub D (2024). "Parkinson's Disease and Dementia with Lewy Bodies: One and the Same". Journal of Parkinson's Disease. 14 (3): 383–397. doi:10.3233/JPD-240002. PMC   11091584 . PMID   38640172.
  14. 1 2 3 Wagaskar P, Gaikwad S, Suryawanshi M, Patil A (September 2025). "The link between oral health and neurodegeneration: a review of periodontitis in Alzheimer's and Parkinson's disease and dementia". Inflammopharmacology. 33 (9): 5023–5036. doi:10.1007/s10787-025-01888-7. PMID   40796989.
  15. Taylor A, Yardley C (2014). "Advocacy, education, and the role of not-for-profit organizations in Lewy body dementias". Alzheimer's Research & Therapy (Review). 6 (5) 59. doi: 10.1186/s13195-014-0059-0 . PMC   4468791 . PMID   26082807.